HOME > ARCHIVE

ARCHIVE

BUSINESS NEWS IN BRIEF

March 14, 2005
Interstitial Pneumonia Due to Arava Evaluated: Safety Inf. No. 201

March 14, 2005
DIAGNOSTIC NEWS IN BRIEF

March 14, 2005
PMDA Suspends Receipt of Applications for Clinical Trial Consultation

March 14, 2005
TOPICS 2 articrels

March 14, 2005
3-Year Plan on Clinical Trials Enters Last Year

March 14, 2005
BULLETIN

March 14, 2005
SJP SEMINAR

March 14, 2005
REGULATORY NEWS IN BRIEF

March 14, 2005
NEW PRODUCTS

March 14, 2005
3M Pharm, Takeda to Collaborate on Treatment for HPV Infection

March 14, 2005
Takeda Obtains Candesartan Add. Indication for Heart Failure

March 14, 2005
DIA Workshop on Clinical Trials Discusses AE Reporting

March 14, 2005
Execommunications to Acquire Kobashou's Subsidiary Kics

March 14, 2005
RESEARCH & DEVELOPMENT NEWS IN BRIEF

March 14, 2005
Nippon Shinyaku Forecasts 2.1% Growth in Sales for FY2004

March 14, 2005
PRESS SEMINAR

March 14, 2005
Mochida's R&D to Focus on Lifestyle Diseases, Chronic Pain

March 14, 2005
OTC NEWS IN BRIEF

March 14, 2005
VIWES & OPINIONS

March 14, 2005

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Shift Underway in Pharma Workforce as Sales Roles Shrink, Manufacturing Rises

By Hayate Horiguchi

Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…